Literature DB >> 3513881

Comparison of the parasympatholytic activity of ACC-9358 and disopyramide.

B S Brown, R J Gorczynski, R D Reynolds, J E Shaffer.   

Abstract

ACC-9358 (N-[(3,5-di(pyrrolidinylmethyl)-4-hydroxy)benzoyl]aniline) is a newly developed analogue of changrolin, an antiarrhythmic agent used in the Peoples Republic of China. Since changrolin and other antiarrhythmic agents exert parasympatholytic activity which may limit their clinical usefulness, it was of interest to examine the parasympatholytic effects of ACC-9358. For comparative purposes we also studied the parasympatholytic activity of disopyramide. In guinea-pig isolated ileal strips, disopyramide, 3-30 microM, and ACC-9358, 100-300 microM, competitively antagonized carbachol-induced contractions with pA2 values of 5.78 and 4.17, respectively. In guinea-pig isolated right atria, disopyramide 3-30 microM, competitively antagonized methacholine-induced slowing of spontaneous beating with a pA2 value of 5.99 whereas ACC-9358, 3-300 microM, produced no significant muscarinic blockade in this preparation. Disopyramide (1.9-15 mg kg-1, i.v.), but not ACC-9358 (7.5-1.5 mg kg-1, i.v.), significantly increased rat pupil diameter in vivo. Disopyramide and ACC-9358 blocked vagal-induced reductions in heart rate in dogs anaesthetized with pentobarbitone. ED50 values were approximately 0.65 and 11.25 mg kg-1, respectively. We conclude that ACC-9358 possesses significantly less parasympatholytic activity than disopyramide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513881      PMCID: PMC1916896          DOI: 10.1111/j.1476-5381.1986.tb10160.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  [Cardiovascular effect of a new antiarrhythmic drug--changrolin (author's transl)].

Authors:  W Z Chen; Y L Dong; G S Ding
Journal:  Yao Xue Xue Bao       Date:  1979-12

2.  Electrophysiological effects of changrolin, a new antiarrhythmic drug, on isolated cardiac preparations.

Authors:  Y Q Xu; E Carmeliet
Journal:  Arch Int Pharmacodyn Ther       Date:  1981-10

3.  Comparative anticholinergic potencies of R- and S- disopyramide in longitudinal muscle strips from guinea pig ileum.

Authors:  K M Giacomini; B M Cox; T F Blaschke
Journal:  Life Sci       Date:  1980-09-29       Impact factor: 5.037

4.  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 2. Amides.

Authors:  D M Stout; W L Matier; C Barcelon-Yang; R D Reynolds; B S Brown
Journal:  J Med Chem       Date:  1984-10       Impact factor: 7.446

5.  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 3. Modifications to the linkage region (region 3).

Authors:  D M Stout; W L Matier; C Barcelon-Yang; R D Reynolds; B S Brown
Journal:  J Med Chem       Date:  1985-03       Impact factor: 7.446

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Anticholinergic effects of disopyramide and quinidine on guinea pig myocardium. Mediation by direct muscarinic receptor blockade.

Authors:  M J Mirro; A S Manalan; J C Bailey; A M Watanabe
Journal:  Circ Res       Date:  1980-12       Impact factor: 17.367

8.  Synthesis and antiarrhythmic and parasympatholytic properties of substituted phenols. 1. Heteroarylamine derivatives.

Authors:  D M Stout; W L Matier; C Barcelon-Yang; R D Reynolds; B S Brown
Journal:  J Med Chem       Date:  1983-06       Impact factor: 7.446

9.  Studies on a new antiarrhythmic drug changrolin-4-(3',5'-bis [(N-pyrrolidinyl) methyl]-4'-hydroxyanilino)-quinazoline.

Authors:  L Q Li; Z X Qu; Z M Wang; Y L Zeng; G S Ding; G J Hu; X Y Yang
Journal:  Sci Sin       Date:  1979-10
  9 in total
  1 in total

1.  A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.

Authors:  J Longmore; J L Berry; E Szabadi; C M Bradshaw
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.